Deerfield Management Company, L.P. (Series C) Biomarin Pharmaceutical Inc Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 9,255 shares of BMRN stock, worth $573,162. This represents 0.01% of its overall portfolio holdings.
Number of Shares
9,255
Previous 9,832
5.87%
Holding current value
$573,162
Previous $809,000
19.65%
% of portfolio
0.01%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding BMRN
# of Institutions
636Shares Held
177MCall Options Held
2.01MPut Options Held
1.28M-
Black Rock Inc. New York, NY22.7MShares$1.41 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.3MShares$1.19 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.9MShares$1.17 Billion0.99% of portfolio
-
Dodge & Cox San Francisco, CA13.9MShares$861 Million0.59% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.5MShares$650 Million0.16% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $11.5B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...